William D. Turner - 08 Dec 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Regulatory Officer
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
08 Dec 2025
Net transactions value
-$297,753
Form type
4
Filing time
10 Dec 2025, 16:05:05 UTC
Previous filing
04 Dec 2025
Next filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Turner William D. Chief Regulatory Officer C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE /s/ Joseph R. Young, Attorney-in-Fact 10 Dec 2025 0001819688

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $155,300 +10,000 +44% $15.53 32,500 08 Dec 2025 Direct
transaction VERA Class A Common Stock Sale $453,053 -10,000 -31% $45.31 22,500 08 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Options Exercise $0 -10,000 -3.8% $0.000000 255,000 08 Dec 2025 Class A Common Stock 10,000 $15.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025.
F2 The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $45.00 to $45.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date.